Publications by Professor Quentin Anstee - ePrints

Browsing publications by Professor Quentin Anstee.

Newcastle Authors	Title	Year
Dr Rebecca Darlay Professor Heather Cordell Professor Quentin Anstee Professor Ann Daly	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation	2022
Professor Quentin Anstee	An international survey on patterns of practice in NAFLD and expectations for therapies—The POP-NEXT project	2022
Tim Hicks Dr Will Jones Dr Jana Suklan Professor Quentin Anstee	Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study	2022
Dr Dina Tiniakos Professor Quentin Anstee	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD	2022
Professor Quentin Anstee	Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis	2022
Helen Jarvis Hannah O'Keefe Professor Dawn Craig Dr Daniel Stow Professor Barbara Hanratty et al.	Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis	2022
Professor Quentin Anstee	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study	2022
Dr Katherine Johnson Dr Peter Leary Dr Olivier Govaere Dr Matthew Barter Sarah Charlton et al.	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance	2022
Dr Marie Boyle Dr Stuart McPherson Professor Arun Sanyal Professor Quentin Anstee	Letter: non-invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply	2022
Dr Olivier Govaere Dr Rebecca Darlay Dr Julien Peltier Dr Jeremy Palmer Dr Massimo Younes et al.	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease	2022
Dr Olivier Govaere Professor Ann Daly Professor Quentin Anstee	Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease	2022
Professor Quentin Anstee	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles	2022
Dr Paula Iruzubieta Professor Quentin Anstee	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles	2022
Professor Quentin Anstee Professor Arun Sanyal	Noninvasive Evaluation of Response to Obeticholic Acid in Patients with NASH: Results from the REGENERATE Study	2022
Professor Quentin Anstee	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials	2022
Dr Sam Tingle Dr Emily Thompson Lucy Bates Dr Ibrahim Ibrahim Dr Olivier Govaere et al.	Pharmacological testing of therapeutics using normothermic machine perfusion: A pilot study of 2,4-dinitrophenol delivery to steatotic human livers	2022
Jadine Scragg Dr Sarah Charman Dr Vincent van Hees Dr Leah Avery Dr Guy Taylor et al.	Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease	2022
Dr Stuart McPherson Professor Quentin Anstee Dr Kate Hallsworth Helen Jarvis Dr Dina Mansour et al.	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group	2022
Professor Quentin Anstee Dr Kate Hallsworth	Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions	2022
Professor Quentin Anstee	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score	2022
Professor Quentin Anstee	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH	2021
Professor Quentin Anstee	A molecular signature for the metabolic syndrome by urine metabolomics	2021
Nardeen Eldafashi Dr Rebecca Darlay Dr Ruchi Shukla Misti McCain Robyn Watson et al.	A pdcd1 role in the genetic predisposition to nafld-hcc?	2021
Professor Quentin Anstee	A Randomized Controlled Trial of the PanPPAR Agonist Lanifibranor in NASH	2021
Professor Quentin Anstee	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis	2021
Dr Massimo Younes Dr Olivier Govaere Dr Dina Tiniakos Professor Alastair Burt Marco Zaki et al.	Caucasian Lean Subjects with Non-Alcoholic Fatty Liver Disease Share Long-Term Prognosis of Non-Lean: Time for Reappraisal of BMI-Driven Approach?	2021
Professor Arun Sanyal Professor Quentin Anstee	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis	2021
Professor Quentin Anstee Professor Arun Sanyal	Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study	2021
Professor Quentin Anstee	Diagnostic Accuracy of Elastography and Magnetic Resonance Imaging in Patients with NAFLD: a systematic review and meta-analysis	2021
Dr Massimo Younes Shilpa Aggarwal Dr Himanshu Garg Professor Quentin Anstee	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD – An individual patient data meta-analysis	2021
Professor Quentin Anstee	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review	2021
Dr Kate Hallsworth Dr Stuart McPherson Professor Quentin Anstee Laura Haigh Dr Leah Avery et al.	Digital Intervention with Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults with Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping	2021
Dr Dina Mansour Professor Quentin Anstee Dr Stuart McPherson	Embedding assessment of liver fibrosis into routine diabetic review in primary care	2021
Jadine Scragg Dr Kate Hallsworth Guy Taylor Dr Sophie Cassidy Laura Haigh et al.	Factors associated with engagement and adherence to a low energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease	2021
Dr Laura Neilson Dr Louise MacDougall Dr Timothy Hardy Dr David Beaton Dr April Phaw et al.	Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease	2021
Marco Zaki Dr Ahmed Mahdi Dr Gillian Patman Anna Whitehead Joao Mauricio et al.	Key features of the environment promoting liver cancer in the absence of cirrhosis	2021
Dr Jack Leslie Dr Emma Scott Professor Quentin Anstee Professor Fiona Oakley	Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma	2021
Dr Massimo Younes Dr Olivier Govaere Dr Dina Tiniakos Professor Alastair Burt Marco Youssef William Zaki et al.	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	2021
Professor Quentin Anstee	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	2021
Dr Olivier Govaere Dr Dina Tiniakos Professor Pierre Bedossa Dr Simon Cockell Dr Massimo Younes et al.	NASH limits anti-tumor surveillance in immunotherapy-treated HCC	2021
Dr Luca Miele Professor Quentin Anstee Professor Helen Reeves	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	2021
Professor Ann Daly Dr Olivier Govaere Professor Quentin Anstee	Peptide-Based Urinary Monitoring of Fibrotic Non-Alcoholic Steatohepatitis by Mass Barcoded Activity-Based Sensors	2021
Professor Quentin Anstee	Prognostic accuracy of FIB-4, NAFLD fibrosis score, and APRI for NAFLD-related events: a systematic review	2021
Professor Quentin Anstee Priyadarshini Basu Dr Pallav Bhatnagar Professor Ann Daly	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis	2021
Professor Quentin Anstee	Systematic review with meta-analyses: Diagnostic accuracy of fibrometer tests in patients with non-alcoholic fatty liver disease	2021
Professor Quentin Anstee	Systematic review with meta-analysis: Diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease	2021
Professor Quentin Anstee	The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis	2021
Professor Quentin Anstee	The European ‘NAFLD Preparedness Index’ — is Europe ready to meet the challenge of fatty liver disease?	2021
Dr John Lazarus Professor Quentin Anstee	The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?	2021
Helen Jarvis Dr Stuart McPherson Professor Quentin Anstee Professor Barbara Hanratty	The pathway to better primary care for chronic liver disease	2021
Dr Olivier Govaere Dr Simon Cockell Professor Ann Daly Professor Quentin Anstee	Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis	2021
Professor Pierre Bedossa Professor Quentin Anstee Professor Arun Sanyal	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study	2020
Professor Quentin Anstee	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe	2020
Professor Arun Sanyal Professor Quentin Anstee	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial	2020
Professor Quentin Anstee	Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis	2020
Dr Batoul Nasr Professor Quentin Anstee Dr Stuart McPherson	Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis	2020
Dr Olivier Govaere Dr Dina Tiniakos Professor Quentin Anstee Professor Fiona Oakley	Bone Morphogenic Protein 8B Promotes the Progression of Non-Alcoholic Steatohepatitis	2020
Professor Quentin Anstee	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design	2020
Professor Quentin Anstee	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis	2020
Dr Olivier Govaere Professor Quentin Anstee	Erratum: Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC	2020
Dr Matthew Breckons Dr Yemi Oluboyede Professor Luke Vale Dr Laura Ternent Professor Arun Sanyal et al.	Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis	2020
Professor Quentin Anstee	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes	2020
Jadine Scragg Dr Leah Avery Dr Sophie Cassidy Dr Guy Taylor Laura Haigh et al.	Feasibility of a very low calorie diet to achieve a sustainable 10% weight loss in patients with non-alcoholic fatty liver disease	2020
Professor Quentin Anstee Professor Pierre Bedossa	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study	2020
Professor Quentin Anstee Dr Rebecca Darlay Dr Simon Cockell Dr Olivier Govaere Dr Dina Tiniakos et al.	Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort	2020
Dr Lorraine McSweeney Dr Matthew Breckons Dr Gulnar Fattakhova Professor Luke Vale Dr Laura Ternent et al.	Health-Related Quality of Life and Patient-Reported Outcome Measures in NASH-related Cirrhosis	2020
Dr Olivier Govaere Professor Quentin Anstee	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers	2020
Helen Jarvis Professor Dawn Craig Dr Robert Barker Dr Gemma Frances Spiers Dr Daniel Stow et al.	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population based observational studies	2020
Helen Jarvis Hannah O'Keefe Professor Dawn Craig Dr Daniel Stow Professor Quentin Anstee et al.	People with NAFLD also drink alcohol - how should we advise and manage this expanding group in primary care? A systematic review.	2020
Dr Massimo Younes Dr Olivier Govaere Dr Dina Tiniakos Professor Alastair Burt Marco Zaki et al.	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease	2020
Dr Massimo Younes Dr Olivier Govaere Dr Luca Miele Dr Dina Tiniakos Professor Alastair Burt et al.	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease	2020
Dr Dina Tiniakos Susan Harrison Professor Quentin Anstee	qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients with Non-Alcoholic Steatohepatitis	2020
Professor Quentin Anstee	Reply to: “Caveats for the implementation of global strategies against non-alcoholic fatty liver disease”	2020
Professor Quentin Anstee	Reply to: “Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease”	2020
Professor Quentin Anstee	Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis due to NASH: Results from the STELLAR Phase 3 Trials	2020
Professor Quentin Anstee	The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study	2020
Dr Timothy Hardy Kristy Wonders Dr Massimo Younes Professor Pierre Bedossa Entesar Betelmal et al.	The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease	2020
Professor Quentin Anstee	The times they are a-changin' (for NAFLD as well)	2020
Dr Olivier Govaere Dr Simon Cockell Dr Dina Tiniakos Dr Rachel Queen Dr Massimo Younes et al.	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis	2020
Professor Quentin Anstee Professor Pierre Bedossa	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease	2019
Laura Haigh Dr Dave Houghton Elsbeth Henderson Dr Leah Avery Dr Timothy Hardy et al.	Barriers and Facilitators to Mediterranean Diet Adoption by Patients with Non-alcoholic Fatty Liver Disease in Northern Europe.	2019
Professor Quentin Anstee Dr David Price Dr Brendan Payne	Central obesity and non-alcoholic fatty liver disease in people living with HIV: a case for targeted screening?	2019
Dr Federico Ravaioli Professor Quentin Anstee	Editorial: collagen proportionate area as a prognostic indicator in NAFLD	2019
Professor Quentin Anstee Professor Helen Reeves Dr Olivier Govaere	From NASH to HCC: current concepts and future challenges	2019
Dr Marie Boyle Kate Hallsworth Dr Dina Tiniakos Professor Quentin Anstee	Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation.	2019
Professor Quentin Anstee	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials	2019
Professor Quentin Anstee Professor Pierre Bedossa Professor Arun Sanyal	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial	2019
Dr Marie Boyle Dr Dina Tiniakos Dr Olivier Govaere Dr Massimo Younes Dr Stuart McPherson et al.	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease	2019
Professor Arun Sanyal Professor Quentin Anstee Professor Pierre Bedossa	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis	2019
Professor Arun Sanyal Professor Quentin Anstee	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD	2019
Dr Dave Houghton Dr Kate Hallsworth Dr Sophie Cassidy Christian Thoma Dr Leah Avery et al.	The degree of hepatic steatosis associates with impaired cardiac and autonomic function	2019
Dr Kate Hallsworth Dr Stephan Dombrowski Dr Stuart McPherson Professor Quentin Anstee Dr Leah Avery et al.	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study	2019
Professor Loranne Agius Professor Quentin Anstee	Application of long single-stranded DNA donors in genome editing: Generation and validation of mouse mutants	2018
Professor Loranne Agius Professor Quentin Anstee	Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants	2018
Dr John Brain Professor Alastair Burt Professor Quentin Anstee	Author correction: Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity	2018
Professor Quentin Anstee	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science	2018
Dr Marie Boyle Professor Quentin Anstee	Editorial: hepatocellular carcinoma in non-cirrhotic NASH - a troubling reality	2018
Dr John Brain Professor Quentin Anstee	Erratum to: Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity (Nature, (2017), 551, 7680, (340-345), 10.1038/nature24302)	2018
Professor Quentin Anstee	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale.	2018
Dr Dina Tiniakos Professor Quentin Anstee Professor Alastair Burt	Fatty Liver Disease	2018
Emma Scott Professor Quentin Anstee	Genetics of alcoholic liver disease and non-alcoholic steatohepatitis	2018
Professor Quentin Anstee Dr Timothy Hardy	Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention	2018
Professor Quentin Anstee Professor Chris Day Professor Arun Sanyal	Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030	2018
Professor Quentin Anstee	Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis	2018
Professor Quentin Anstee	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany	2018
Professor Quentin Anstee	Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study	2018
Professor Quentin Anstee	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease	2018
Dr Marie Boyle Dr Steven Masson Professor Quentin Anstee	The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease	2018
Dr Emma Scott Professor Quentin Anstee	The genetics of alcoholic liver disease and non-alcoholic steatohepatitis	2018
Dr Olivier Govaere Professor Quentin Anstee	Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis	2018
Professor Quentin Anstee	Thrombin and factor Xa link the coagulation system with liver fibrosis	2018
Dr Stuart McPherson Dr Nina Wilson Dr Dina Tiniakos Dr Jennifer Wilkinson Professor Alastair Burt et al.	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis	2017
Dr Stuart McPherson Dr Timothy Hardy Dr Dina Tiniakos Professor Alastair Burt Professor Chris Day et al.	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis	2017
Dr Dave Houghton Dr Sophie Cassidy Dr Christian Thoma Dr Kate Hallsworth Dr Leah Avery et al.	Autonomic function is impaired across the spectrum of NAFLD	2017
Professor Quentin Anstee Professor Arun Sanyal	Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum	2017
Dr David Sheridan Professor Quentin Anstee Dr Stuart McPherson	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey	2017
Dr Mikolaj Ogrodnik Dr Satomi Miwa Dr Dina Tiniakos Dr Caroline Wilson Professor Chris Day et al.	Cellular senescence drives age-dependent hepatic steatosis	2017
Dr Dave Houghton Dr Kate Hallsworth Dr Christian Thoma Dr Sophie Cassidy Dr Timothy Hardy et al.	Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers	2017
Dr Dave Houghton Christian Thoma Dr Kate Hallsworth Dr Sophie Cassidy Dr Timothy Hardy et al.	Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial	2017
Professor Quentin Anstee	Genetic variation in GABRβ1 and the risk for developing alcohol dependence	2017
Dr Emma Scott Dr Jeremy Palmer Professor Quentin Anstee	Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD	2017
Dr John Brain Professor Alastair Burt Professor Quentin Anstee	Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity	2017
Dr Leah Avery Professor Catherine Exley Dr Stuart McPherson Professor Mike Trenell Professor Quentin Anstee et al.	Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice	2017
Misti McCain Dr Luca Miele Dr Paula Iruzubieta Professor Helen Reeves Professor Quentin Anstee et al.	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals	2017
Professor Quentin Anstee	NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD	2017
Professor Quentin Anstee	Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases	2017
Dr Timothy Hardy Dr Mujdat Zeybel Professor Chris Day Dr Christian Dipper Dr Steven Masson et al.	Plasma DNA methylation: A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease	2017
Dr Lucy Walker Professor Ann Daly Dr Luca Miele Professor Quentin Anstee Professor Helen Reeves et al.	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease	2017
Dr Olivier Govaere Professor Quentin Anstee	The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma	2017
Professor Quentin Anstee Dr Yang-Lin Liu Dr Rebecca Darlay Professor Heather Cordell Professor Ann Daly et al.	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans	2017
Professor Quentin Anstee	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study	2017
Professor Quentin Anstee	A fatty liver leads to a broken heart?	2016
Professor Quentin Anstee Professor Arun Sanyal	ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial	2016
Dr Stuart McPherson Professor Quentin Anstee	Changing Epidemiology of Chronic Liver Disease Among Ethnic Groups in the United States	2016
Dr Dina Tiniakos Professor Quentin Anstee Professor Chris Day Professor Alastair Burt Dr John Brain et al.	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference	2016
Professor Quentin Anstee	Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening	2016
Dr Dave Houghton Dr Sophie Cassidy Dr Kate Hallsworth Dr Kieren Hollingsworth Professor Roy Taylor et al.	Exercise reduces liver fat and improves body composition but not insulin sensitivity or inflammatory markers in non-alcoholic steatohepatitis	2016
Professor Quentin Anstee Professor Chris Day	Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease	2016
Dr Nimantha de Alwis Professor Quentin Anstee Professor Chris Day	How to Diagnose Nonalcoholic Fatty Liver Disease	2016
Professor Quentin Anstee Professor Arun Sanyal	Improvement in NASH histological activity highly correlates with fibrosis regression	2016
Dr Timothy Hardy Professor Fiona Oakley Professor Quentin Anstee Professor Chris Day	Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum	2016
Professor Quentin Anstee	Novel Fibroscan-Based Score to Diagnose NASH and its severity in A Multi-centre UK Cohort of Patients with Suspected NAFLD	2016
Professor Quentin Anstee	Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis	2016
Professor Quentin Anstee Dr David Sheridan	Staging fibrosis and excluding advanced fibrosis in patients with NAFLD: comparison of non-invasive markers in an interim analysis from a prospective multicentre study	2016
Professor Quentin Anstee Professor Arun Sanyal	Validation of mir-34a, mir-122 and mir-200a as bio-markers for identification of NASH patients eligible for treatment	2016
Professor Quentin Anstee	An overview of the genetics, mechanisms and management of NAFLD and ALD	2015
Professor Quentin Anstee	An overview of the genetics, mechanisms and management of NAFLD and ALD	2015
Dr Mujdat Zeybel Dr Timothy Hardy Stuart Robinson Christopher Fox Professor Quentin Anstee et al.	Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease	2015
Anna Whitehead Dr Gillian Patman Professor Chris Day Dr Dina Tiniakos Professor Quentin Anstee et al.	Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease	2015
Dr Stuart McPherson Dr Timothy Hardy Elsbeth Henderson Professor Alastair Burt Professor Chris Day et al.	Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management	2015
Dr Dave Houghton Dr Christian Thoma Dr Kate Hallsworth Dr Kieren Hollingsworth Professor Chris Day et al.	Exercise reduces liver fat, visceral fat and circulating triglycerides, but not circulating inflammatory markers in non-alcoholic steatohepatitis	2015
Professor Quentin Anstee Professor Ann Daly Professor Chris Day	Genetics of Alcoholic Liver Disease	2015
Dr Stuart McPherson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al.	High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (>=65 years) with NAFLD	2015
Dr Timothy Hardy Victoria Sharkey Dr Mujdat Zeybel Professor John Mathers Steven White et al.	Laser capture microdissection reveals cell-specific DNA methylation signatures in key fibrosis modifier genes in chronic liver disease	2015
Dr Jeremy Palmer Dr Yang-Lin Liu Professor Chris Day Professor Ann Daly Professor Quentin Anstee et al.	Mechanistic Study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress	2015
Dr Kate Hallsworth Christian Thoma Dr Kieren Hollingsworth Dr Sophie Cassidy Professor Quentin Anstee et al.	Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomised controlled trial	2015
Dr Jess Dyson Professor Quentin Anstee Dr Stuart McPherson	Non-alcoholic fatty liver disease: a practical approach to treatment	2015
Professor Chris Day Professor Quentin Anstee	Nonalcoholic Fatty Liver Disease: Foreword	2015
Dr Timothy Hardy Professor Quentin Anstee Professor Chris Day	Nonalcoholic fatty liver disease: new treatments	2015
Anna Whitehead Laura Ogle Dr Gillian Patman Dr Ali Anwar Dr Dina Tiniakos et al.	Ras and p-ERK in metabolic syndrome associated Hepatocellular Carcinoma (HCC)	2015
Professor Quentin Anstee Dr Yang-Lin Liu Professor Chris Day Professor Helen Reeves	Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance	2015
Professor Helen Reeves Dr Luca Miele Professor Quentin Anstee	Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash	2015
Rodolphe Anty Professor Chris Day Professor Ann Daly Anh Tran Professor Quentin Anstee et al.	The FNDC5 rs3480 is protective on the steatosis and fibrosis in patients with NAFLD	2015
Professor Quentin Anstee Professor Chris Day	The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2	2015
Professor Quentin Anstee	The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity	2015
Professor Ann Daly Professor Chris Day Dr Yang-Lin Liu Professor Quentin Anstee	TM6SF2 as a Genetic Risk Factor for Fibrosis	2015
Dr Yang-Lin Liu Professor Ann Daly Professor Chris Day Professor Quentin Anstee	TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?	2015
Professor Quentin Anstee Professor Chris Day	Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis	2015
Dr Stuart McPherson Professor Quentin Anstee	Wafarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year	2015
Dr Yang-Lin Liu Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al.	Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma	2014
Dr Mujdat Zeybel Dr Timothy Hardy Christopher Fox Dr Steven Masson Professor Derek Mann et al.	Differential DNA methylation of genes involved in fibrosis progression in NAFLD and ALD	2014
Julian Leathart Professor Ann Daly Professor Chris Day Professor Quentin Anstee	Gene Polymorphisms of Cellular Senescence Marker P21 and Disease Progression in Non-Alcohol-Related Fatty Liver Disease	2014
Professor Quentin Anstee	Liver and Biliary Tract Disease	2014
Rodolphe Anty Professor Quentin Anstee	Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients	2014
Dr Stuart McPherson Elsbeth Henderson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day et al.	Natural history of NAFLD: A study of 108 patients with paired liver biopsies	2014
Dr Stuart McPherson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al.	Natural History of NAFLD: A Study of 108 Patients with Paired Liver Biopsies	2014
Dr Kate Hallsworth Dr Christian Thoma Sarah Moore Dr Thomas Ploetz Professor Quentin Anstee et al.	Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls	2014
Dr Jess Dyson Dr Stuart McPherson Professor Quentin Anstee	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification	2014
Rodolphe Anty Professor Quentin Anstee	Prophylaxis of bacterial infections in cirrhosis: Is an optimal 25-OH vitamin D level required?	2014
Professor Quentin Anstee Dr Mark Hudson Professor Helen Reeves	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area"	2014
Dr Stuart McPherson Elsbeth Henderson Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al.	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease	2014
Dr Yang-Lin Liu Professor Helen Reeves Professor Alastair Burt Dr Dina Tiniakos Dr Stuart McPherson et al.	TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease	2014
Professor Quentin Anstee Dr Rebecca Darlay Julian Leathart Yilei Liu Professor Alastair Burt et al.	A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease	2013
Anna Whitehead Dr Gillian Patman Liam Cornell Dr Despina Televantou Professor Nicola Curtin et al.	A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)?	2013
Dr Stuart McPherson Professor Quentin Anstee Professor Chris Day Professor Alastair Burt	Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?	2013
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Djordje Jakovljevic Dr Guy MacGowan et al.	Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease	2013
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Djordje Jakovljevic Dr Guy MacGowan et al.	Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease	2013
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Quentin Anstee Professor Chris Day et al.	Cardiac Function Improves Following High Intensity Intermittent Exercise Therapy in Non-Alcoholic Fatty Liver Disease	2013
Dr Kate Hallsworth Dr Kieren Hollingsworth Dr Christian Thoma Professor Djordje Jakovljevic Dr Guy MacGowan et al.	Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease	2013
Dr Yang-Lin LIU Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al.	Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma	2013
Professor Quentin Anstee Dr Steven Masson Dr Stuart McPherson	Does the Pre-Bone Mineral Density Frax Score Predict Fracture Risk in Patients with Cirrhosis?	2013
Professor Quentin Anstee	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment	2013
Dr Kate Hallsworth Dr Christian Thoma Professor Quentin Anstee Professor Chris Day Professor Mike Trenell et al.	Higher Objectively Measured Sedentary Behaviour and Lower Levels of Physical Activity than Matched Healthy Controls	2013
Dr Christian Thoma Dr Kate Hallsworth Dr Kieren Hollingsworth Professor Quentin Anstee Professor Chris Day et al.	HIGH-INTENSITY INTERMITTENT EXERCISE THERAPY REDUCES LIVER FAT AND IMPROVES BODY COMPOSITION IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE	2013
Professor Quentin Anstee Dr Yang-Lin Liu Professor Heather Cordell Dr Rebecca Darlay Professor Chris Day et al.	Mapping Expression Quantitative Traits Loci (EQTL) for PNPLA3 Gene Identifies Additional SNPs Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of rs738409	2013
Dr Gillian Patman Dr Despina Televantou Anna Whitehead Professor Chris Day Professor Fiona Oakley et al.	Mild Steatosis and Impaired Glucose Tolerance are Associated with Liver Cancer Development, While Progression to Nash Increases Number/Size in an Animal Model of NAFLD	2013
Professor Quentin Anstee	Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice	2013
Professor Quentin Anstee	Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition	2013
Dr Jess Dyson Dr Stuart McPherson Professor Quentin Anstee	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification	2013
Professor Quentin Anstee Professor Chris Day	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis	2013
Professor Quentin Anstee	Rifaximin in Non-Alcoholic Steatohepatitis an Open-Label Pilot Study	2013
Professor Quentin Anstee	Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study	2013
Professor Quentin Anstee Professor Chris Day	The genetics of NAFLD	2013
Professor Quentin Anstee Professor Chris Day	S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility	2012
Professor Quentin Anstee Professor Chris Day	A lipid to treat non-alcoholic fatty liver disease – The dawn of ‘lipo-rehabilitation’?	2012
Professor Quentin Anstee	A role for anticoagulation in fibrogenesis: Supression of human hepatic stellate cell contractility and liver fibrosis in vitro and vivo	2012
Professor Quentin Anstee Dr Rebecca Darlay Julian Leathart Professor Helen Reeves Professor Alastair Burt et al.	Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD	2012
Professor Quentin Anstee	H-1-NMR metabolic profiling in germ-free and conventionally housed mouse models of acetaminophen-induced hepatotoxicity	2012
Dr Gillian Patman Douglas Hui Professor Quentin Anstee Professor Helen Reeves	Kruppel-like factor 6 splice variant 3 (KLF6-SV3) - The redox sensitive splice variant of KLF6 expressed in non-alcoholic steatohepatitis (NASH)	2012
Professor Quentin Anstee	Measuring the effectiveness of a multidisciplinary non-alcoholic fatty liver disease clinic	2012
Dr Mujdat Zeybel Dr Timothy Hardy Frances Wong Professor John Mathers Christopher Fox et al.	Multigenerational epigenetic adaptation of the hepatic wound-healing response	2012
Dr Gillian Patman Douglas Hui Professor Quentin Anstee Professor Helen Reeves	Oxidative stress induces alternative splicing and nuclear translocation of kruppel like factor 6	2012
Professor Quentin Anstee	Quantifying hepatic steatosis - more than meets the eye	2012
Professor Quentin Anstee	Targeted inhibition of tissue factor and thrombin on CD31 expressing cells suppresses hepatic fibrosis in CCl4 treated mice	2012
Professor Quentin Anstee	Targeted inhibition of tissue factor and thrombin on CD31 expressing cells supresses hepatic fibrosis in CCL4 treated mice	2012
Professor Quentin Anstee	Targeted inhibition of Tissue Factor suppresses hepatic fibrosis in CCL4 treated mice	2012
Ahmad Alserri Professor Quentin Anstee Julian Leathart Julia Patch Professor Chris Day et al.	The SOD2 C₄₇T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies	2012
Dr Stuart McPherson Dr Timothy Hardy Professor Alastair Burt Professor Chris Day Professor Quentin Anstee et al.	The FIB-4 score reliability excludes advanced fibrosis in a diabetic cohort with NAFLD	2012
Professor Quentin Anstee	A novel mouse model of hepatic glycogen storage disease Type 3 identified using a phenotype-driven ethyl-nitrosourea (ENU) mutagensis screen	2011
Professor Quentin Anstee	Activating Autophagocytosis Decreases Fat Within the Liver	2011
Professor Quentin Anstee	Animal models in nonalcoholic steatohepatitis research: utility and clinical translation	2011
Dr Stuart McPherson Professor Quentin Anstee Elsbeth Henderson Professor Alastair Burt Professor Chris Day et al.	Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?	2011
Professor Quentin Anstee Professor Ann Daly Professor Chris Day	Genetic modifiers of non-alcoholic fatty liver disease progression	2011
Professor Quentin Anstee Professor Ann Daly Professor Chris Day	Genetics of alcoholic liver disease and nonalcoholic fatty liver disease	2011
Dr Gillian Patman Professor Quentin Anstee Professor Helen Reeves	Hepatocellular Carcinoma in NASH: Is there a biological Rationale?	2011
Professor Quentin Anstee Dr Stuart McPherson Professor Chris Day	How big a problem is non-alcoholic fatty liver disease?	2011
Professor Quentin Anstee	Hypercoagulability in cirrhosis: causes and consequences	2011
Professor Quentin Anstee	Multi-Excitation Fluorescence Spectroscopy for Analysis of Non-Alcoholic Fatty Liver Disease	2011
Professor Quentin Anstee	The role of hypercoagulability in liver fibrogenesis	2011
Professor Quentin Anstee	Vanin-1 activity modulates the steatosis-steatohepatitis transition in progressive non-alcoholic steatohepatitis	2011
Professor Quentin Anstee	Cell surface pantetheinase, Vanin-1, increases oxidative damage in acetaminophen-induced liver injury via a reduction in glutathione	2010
Professor Quentin Anstee	Coagulation proteins in acute liver injury: a role in initiation and propagation	2010
Professor Quentin Anstee Brian Smith	Hepatitis B and hepatitis C co-infection	2010
Professor Quentin Anstee	Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis	2010
Professor Quentin Anstee	Is oil red-O and digital image analysis the gold standard for quantifying steatosis in the liver?	2010
Professor Quentin Anstee	Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?	2010
Professor Quentin Anstee	Novel quantitative trait locus for acetaminophen-induced hepatotoxicty identified on chromosome 18	2010
Professor Quentin Anstee	Rational Testing: Investigating mildly abnormal serum aminotransferase values	2010
Professor Quentin Anstee	Role of monocytes and macrophages in experimental and human acute liver failure	2010
Professor Quentin Anstee	A missense mutation in the non-neural G-protein α-subunit isoforms modulates susceptibility to obesity	2009
Professor Quentin Anstee	Autofluorescence: modelling a tool for assessment of steatotic marginal grafts in liver transplantation	2009
Professor Quentin Anstee Professor Matthew Wright	Parenchymal extinction: coagulation and hepatic fibrogenesis	2009
Professor Quentin Anstee	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue	2009
Professor Quentin Anstee	The importance of fatty liver disease in clinical practice	2009
Professor Quentin Anstee Professor Matthew Wright	Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies	2008
Professor Quentin Anstee	Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis	2008
Professor Quentin Anstee	Hypercoagulation and thrombophilia in liver disease	2008
Professor Quentin Anstee	Identification of a model of alcohol preference and its similarity to human alcoholism	2008
Professor Quentin Anstee	Can disease progression in non-alcoholic fatty liver disease be predicted by metabolic biomarkers of lipid accumulation and peroxidation?	2007
Professor Quentin Anstee	Dietary constituents in mice are reflected in the hepatic lipid profile as detected by carbon-13 magic angle spinning magnetic resonance spectroscopy	2007
Professor Quentin Anstee	Microarray analysis demonstrates insulin resistance is central to NASH pathogenesis in the IGT/6 model and suggests a role for CEACAM-1 in disease pathogenesis	2007
Professor Quentin Anstee	Microarray principal components analysis demonstrates expression of Vanin-1 is a strong determinant of NASH pathogenesis in the IGT/6 model	2006
Professor Quentin Anstee	Mouse models in non-alcoholic fatty liver disease and steatohepatitis research	2006
Professor Quentin Anstee Professor Matthew Wright	The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure	2004
Professor Quentin Anstee	A novel murine model of non-alcoholic steatohepatitis generated using a sensitised ENU mutagenesis screen	2003
Professor Quentin Anstee	The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn's disease	2000
Professor Quentin Anstee	[Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease	1999
Professor Quentin Anstee	[Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease	1999
Professor Quentin Anstee	Vectorial function of major histocompatibility complex class II in a human intestinal cell line	1999